哮喘生物制剂：肺功能、激素依赖性和加重。
Asthma Biologics: Lung Function, Steroid-Dependence, and Exacerbations.
机构信息
Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA; Division of Allergy and Immunology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
出版信息
Immunol Allergy Clin North Am. 2024 Nov;44(4):693-708. doi: 10.1016/j.iac.2024.08.002.
The development of multiple targeted biologic therapies over the past two decades has revolutionized the management of asthma. Currently, there are 6 monoclonal antibodies that target specific inflammatory mediators involved in the pathophysiology of asthma, and together, they provide the opportunity for personalized treatment options beyond bronchodilators and inhaled or systemic glucocorticoids in severe and difficult-to-control cases of asthma. These agents are the anti-IgE antibody omalizumab, the anti-IL-5 antibodies mepolizumab and reslizumab, the IL-5 receptor alpha antagonist benralizumab, the IL-4 receptor alpha antagonist dupilumab, and the anti-thymic stromal lymphopoietin antibody tezepelumab.
在过去的二十年中，多种靶向生物疗法的发展彻底改变了哮喘的治疗方式。目前，有 6 种单克隆抗体针对哮喘病理生理学中涉及的特定炎症介质，它们共同为严重和难以控制的哮喘病例提供了除支气管扩张剂和吸入或全身糖皮质激素之外的个性化治疗选择。这些药物包括抗 IgE 抗体奥马珠单抗、抗 IL-5 抗体美泊利单抗和瑞利珠单抗、IL-5 受体α拮抗剂贝那利珠单抗、IL-4 受体α拮抗剂度普利尤单抗以及抗胸腺基质淋巴细胞生成素抗体替西珠单抗。
Zotero 插件